3320.HK · CHINARES PHARMA
Hong Kong · RS rating 64 · As of 2026-10-14
| Price | 4.62 HKD |
|---|---|
| 1-day change | +2.7% |
| RS rating (overall / 1M / 3M / 12M) | 64 / 83 / 55 / 65 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 26 / 22 / 17 |
| Industry group (rank) | Medical-Generic Drugs (–) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +28.9% |
| Market cap (USD) | $3.5B |